Join Growin Stock Community!

Omnicell, inc.OMCL.US Overview

US StockHealthcare
(No presentation for OMCL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OMCL AI Insights

OMCL Overall Performance

OMCL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OMCL Recent Performance

-1.69%

Omnicell, inc.

0.05%

Avg of Sector

-0.31%

S&P500

OMCL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OMCL Key Information

OMCL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OMCL Profile

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Price of OMCL

OMCL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OMCL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.04
PE Ratio (TTM)
1027.50
Forward PE
20.68
PS Ratio (TTM)
1.59
PB Ratio
1.53
Price-to-FCF
27.32
METRIC
VALUE
vs. INDUSTRY
Gross Margin
42.49%
Net Margin
0.17%
Revenue Growth (YoY)
6.53%
Profit Growth (YoY)
6.89%
3-Year Revenue Growth
1.79%
3-Year Profit Growth
2.29%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.04
PE Ratio (TTM)
1027.50
Forward PE
20.68
PS Ratio (TTM)
1.59
PB Ratio
1.53
Price-to-FCF
27.32
Gross Margin
42.49%
Net Margin
0.17%
Revenue Growth (YoY)
6.53%
Profit Growth (YoY)
6.89%
3-Year Revenue Growth
1.79%
3-Year Profit Growth
2.29%

  • When is OMCL's latest earnings report released?

    The most recent financial report for Omnicell, inc. (OMCL) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OMCL's short-term business performance and financial health. For the latest updates on OMCL's earnings releases, visit this page regularly.

  • Where does OMCL fall in the P/E River chart?

    According to historical valuation range analysis, Omnicell, inc. (OMCL)'s current price-to-earnings (P/E) ratio is 928.43, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of OMCL?

    According to the latest financial report, Omnicell, inc. (OMCL) reported an Operating Profit of 415K with an Operating Margin of 0.13% this period, representing a decline of 96.65% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OMCL's revenue growth?

    In the latest financial report, Omnicell, inc. (OMCL) announced revenue of 313.98M, with a Year-Over-Year growth rate of 2.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does OMCL have?

    At the end of the period, Omnicell, inc. (OMCL) held Total Cash and Cash Equivalents of 196.52M, accounting for 0.1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OMCL go with three margins increasing?

    In the latest report, Omnicell, inc. (OMCL) did not achieve the “three margins increasing” benchmark, with a gross margin of 41.5%%, operating margin of 0.13%%, and net margin of -0.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OMCL's profit trajectory and future growth potential.

  • Is OMCL's EPS continuing to grow?

    According to the past four quarterly reports, Omnicell, inc. (OMCL)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OMCL?

    Omnicell, inc. (OMCL)'s Free Cash Flow (FCF) for the period is 18.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 57.04% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OMCL?

    The latest valuation data shows Omnicell, inc. (OMCL) has a Price-To-Earnings (PE) ratio of 928.43 and a Price/Earnings-To-Growth (PEG) ratio of 1.83. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.